2.27
price down icon2.75%   -0.06
 
loading
Maxcyte Inc stock is traded at $2.27, with a volume of 172.01K. It is down -2.75% in the last 24 hours and up +2.30% over the past month. MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$2.33
Open:
$2.29
24h Volume:
172.01K
Relative Volume:
0.20
Market Cap:
$241.03M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-6.6765
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
+5.40%
1M Performance:
+2.30%
6M Performance:
-51.37%
1Y Performance:
-48.73%
1-Day Range:
Value
$2.24
$2.33
1-Week Range:
Value
$2.02
$2.37
52-Week Range:
Value
$2.00
$5.20

Maxcyte Inc Stock (MXCT) Company Profile

Name
Name
Maxcyte Inc
Name
Phone
301-517-5556
Name
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Name
Employee
114
Name
Twitter
Name
Next Earnings Date
2025-03-11
Name
Latest SEC Filings
Name
MXCT's Discussions on Twitter

Compare MXCT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
MXCT
Maxcyte Inc
2.265 238.15M 45.44M -35.43M -25.39M -0.34
Medical Devices icon
ABT
Abbott Laboratories
125.09 218.75B 43.11B 13.98B 6.66B 7.98
Medical Devices icon
BSX
Boston Scientific Corp
105.56 152.62B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
397.70 151.01B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
92.03 117.43B 33.54B 4.66B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
75.58 44.76B 5.54B 4.18B 623.10M 7.00

Maxcyte Inc Stock (MXCT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-22-25 Initiated Stephens Overweight
Nov-29-23 Initiated Craig Hallum Buy
Oct-15-21 Resumed Cowen Outperform
Aug-24-21 Initiated BTIG Research Buy
Aug-24-21 Initiated Cowen Outperform
Aug-24-21 Initiated Stephens Overweight
Aug-24-21 Initiated Stifel Buy
Aug-24-21 Initiated Wedbush Outperform
Aug-24-21 Initiated William Blair Outperform
View All

Maxcyte Inc Stock (MXCT) Latest News

pulisher
Jul 23, 2025

Published on: 2025-07-23 21:52:41 - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives MaxCyte Inc. stock priceFree Technical Analysis Support - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about MaxCyte Inc. stockFree Real-Time Stock Data - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

MaxCyte Inc. Stock Analysis and ForecastHigh-yield capital appreciation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Is MaxCyte Inc. a good long term investmentPhenomenal capital appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 15, 2025

Why MaxCyte Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes MaxCyte Inc. stock price move sharplySwing Trade Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

IWN ETF Implied Analyst Target Price: $198.15 - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

How MaxCyte Inc. stock performs during market volatilityDaily Swing Candidates - Newser

Jul 15, 2025
pulisher
Jul 09, 2025

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times

Jul 09, 2025
pulisher
Jul 09, 2025

MaxCyte, Inc. to Release Second Quarter 2025 Financial Results on August 6th - Nasdaq

Jul 09, 2025
pulisher
Jul 02, 2025

PHC announces exclusive distribution of MaxCyte ExPERT platform in Japan - BioSpectrum Asia

Jul 02, 2025
pulisher
Jul 01, 2025

PHC TO EXCLUSIVELY DISTRIBUTE MAXCYTE CELL ENGINEERING PLATFORM IN JAPAN - bernama

Jul 01, 2025
pulisher
Jul 01, 2025

Business Wire - JIJI PRESS

Jul 01, 2025
pulisher
Jul 01, 2025

PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan - Business Wire

Jul 01, 2025
pulisher
Jun 26, 2025

MaxCyte Cancels AIM Market Trading for Common Stock - TipRanks

Jun 26, 2025
pulisher
Jun 25, 2025

MaxCyte shares trading for last time in London - Sharecast.com

Jun 25, 2025
pulisher
Jun 23, 2025

Moving Gene Editing Advances Into the Clinic - the-scientist.com

Jun 23, 2025
pulisher
Jun 19, 2025

MaxCyte stockholders approve AIM delisting, company to trade only on Nasdaq - Investing.com

Jun 19, 2025
pulisher
Jun 18, 2025

MaxCyte Shareholders Approve Equity Plan Amendment - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

MaxCyte shareholders approve equity plan expansion, AIM delisting - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Analyzing Ratios: MaxCyte Inc (MXCT)’s Financial Story Unveiled - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

MaxCyte shareholders approve equity plan expansion, AIM delisting By Investing.com - Investing.com UK

Jun 18, 2025
pulisher
Jun 13, 2025

California State Teachers Retirement System Sells 82,134 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

MaxCyte & Ori Biotech Integrate Platforms for Efficient Manufacturing - Contract Pharma

Jun 11, 2025
pulisher
Jun 11, 2025

Market news - investments.halifax.co.uk

Jun 11, 2025
pulisher
Jun 11, 2025

MaxCyte enters collaboration with Ori Biotech - Sharecast.com

Jun 11, 2025
pulisher
Jun 11, 2025

MaxCyte (MXCT) Partners with Ori Biotech to Boost Cell Therapy Manufacturing | MXCT Stock News - GuruFocus

Jun 11, 2025

Maxcyte Inc Stock (MXCT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Maxcyte Inc Stock (MXCT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Soleymannezhad Ali
Chief Commercial Officer
Mar 18 '25
Sale
3.18
1,211
3,850
59,439
Sandoval David I.
GENERAL COUNSEL
Mar 18 '25
Sale
3.18
353
1,122
64,219
Swirsky Douglas J
CHIEF FINANCIAL OFFICER
Mar 18 '25
Sale
3.18
6,939
22,061
111,811
Johnston John Joseph
Director
Jan 27 '25
Option Exercise
2.93
3,000
8,796
144,950
Johnston John Joseph
Director
Jan 27 '25
Sale
4.64
3,000
13,935
141,950
Sandoval David I.
GENERAL COUNSEL
Jan 13 '25
Sale
4.54
4,466
20,272
41,447
Johnston John Joseph
Director
Dec 26 '24
Option Exercise
2.93
3,000
8,796
144,950
Johnston John Joseph
Director
Dec 26 '24
Sale
4.01
3,000
12,021
141,950
$287.01
price up icon 0.09%
medical_devices STE
$227.75
price up icon 0.96%
medical_devices PHG
$25.91
price up icon 0.21%
$86.78
price up icon 0.40%
$77.13
price down icon 0.20%
medical_devices EW
$75.66
price down icon 1.53%
Cap:     |  Volume (24h):